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CI = confidence interval; COX = cyclo-oxygenase; MI = myocardial infarction; NSAID = nonsteroidal anti-inflammatory drug; OA = osteoarthritis;
PPI = proton pump inhibitor; RA = rheumatoid arthritis.
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Abstract
Conventional ‘nonselective’ nonsteroidal anti-inflammatory drugs
(NSAIDs) are widely used for the treatment of pain and inflam-
mation; however, the potential gastrointestinal risks associated
with their use can be a cause for concern. In response to the
adverse effects that can accompany nonselective NSAID use,
selective cyclo-oxygenase (COX)-2 inhibitors were developed to
target the COX-2 isoenzyme, thus providing anti-inflammatory and
analgesic benefits while theoretically sparing the gastroprotective
activity of the COX-1 isoenzyme. Data from large-scale clinical
trials have confirmed that the COX-2 inhibitors are associated with
substantial reductions in gastrointestinal risk in the majority of
patients who do not receive aspirin. However, some or all of the
gastrointestinal benefit of COX-2 inhibitors may be lost in patients
who receive low, cardioprotective doses of aspirin, and recent
evidence suggests that some of these agents, at some doses, may
be associated with an increased risk for cardiovascular adverse
events compared with no therapy. The risks and benefits of
conventional NSAIDs and of COX-2 inhibitors must be weighed
carefully; in clinical practice many patients who might benefit from
NSAID or COX-2 therapy are likely to be elderly and at relatively
high risk for gastrointestinal and cardiovascular adverse events.
These patients are also more likely to be taking low-dose aspirin for
cardiovascular prophylaxis and over-the-counter NSAIDs for pain.
Identifying therapies that provide relief from arthritis related
symptoms, confer optimum cardioprotection, and preserve the
gastrointestinal mucosa is complex. Factors to consider include
the interference of certain NSAIDs with the antiplatelet effects of
aspirin, differences in the adverse gastrointestinal event rates
among nonselective NSAIDs and selective COX-2 inhibitors,
emerging data regarding the relative risks for cardiovascular events
associated with these drugs, and the feasibility and cost of co-
therapy with proton pump inhibitors.
Introduction
Conventional nonsteroidal anti-inflammatory drugs (NSAIDs;
relatively  nonselective in their inhibition of cyclo-oxygenase
[COX]-1 and COX-2) are widely used for the treatment of
pain and inflammation. However, the deleterious
gastrointestinal effects potentially associated with their use
can be a cause for concern, accounting for approximately
21% of adverse drug reactions reported in the USA [1].
Studies of the COX-2 selective agents (COX-2 inhibitors)
have demonstrated that they are associated with a
significantly reduced risk for upper and lower gastrointestinal
complications compared with conventional NSAIDs, although
recent evidence indicates that this effect is partially or totally
ameliorated in patients who are receiving concomitant aspirin.
Furthermore, recent evidence suggests that at least some of
the COX-2 inhibitors are associated with cardiovascular
adverse effects at certain doses; fewer relevant data are
available for conventional NSAIDs (generally studied many
years ago), although accumulating information suggests that
at least some of these also increase risk for cardiovascular
events.
In clinical practice, patients who require NSAID or COX-2
inhibitor therapy most frequently are those at the highest risk
for cardiovascular events and are also likely to be taking
prophylactic low dose aspirin. Given the interaction between
certain NSAIDs, COX-2 inhibitors, and aspirin, balancing the
benefits and risks of each of these agents is of considerable
importance. This article summarizes the effects of aspirin,
nonaspirin NSAIDs, and COX-2 inhibitors on the gastro-
intestinal tract and cardiovascular system that must be
considered when making treatment decisions in patients who
require these therapies.
Gastroprotective effects of COX-2 inhibitors
The gastrointestinal adverse effects of aspirin and traditional
NSAIDs are well known. Clinically important NSAID related
events, such as bleeding, result in more than 100,000
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hospitalizations and up to 16,500 excess gastrointestinal
event related deaths each year in the USA alone. Endoscopic
studies indicate that gastric or duodenal ulcers develop in
15–30% of patients who regularly take these agents [2].
Recent studies have indicated that the risk for serious NSAID
gastropathy has declined substantially during the past
decade as a result of a number of factors, including lower
doses of NSAIDs, use of proton pump inhibitors (PPIs), and
the introduction of the selective COX-2 inhibitors [3].
The gastrointestinal toxicity of traditional NSAIDs is thought
to be the result of nonselective inhibition of both COX-1 and
COX-2 isoenzymes involved in prostaglandin synthesis [4].
COX-1 is constitutively expressed and generates prostanoids
that are involved in the maintenance of gastrointestinal
mucosa and platelet aggregation. In contrast, COX-2 is
primarily induced to generate prostaglandins that mediate
inflammation and pain [5]. As a result, COX-2 inhibitors were
developed to suppress prostaglandin production by the
COX-2 enzyme selectively, thus providing anti-inflammatory
and analgesic benefits while sparing the gastroprotective
activity of COX-1. Data from large-scale clinical trials have
confirmed that the COX-2 inhibitors are associated with
substantial reductions in gastrointestinal risk in the majority of
patients who do not receive aspirin.
The evidence for reduced gastrointestinal risk with
COX-2 inhibitors
Clinical studies suggest that the COX-2 inhibitors are
associated with a reduction in risk for gastrointestinal adverse
events that is approximately equivalent to the reduction
achieved by adding PPI therapy to traditional NSAIDs.
Endoscopic evidence indicates that COX-2 inhibitors are
associated with a reduced incidence of gastroduodenal ulcers
compared with conventional NSAIDs. In a study conducted by
Laine and colleagues [6] 742 patients with osteoarthritis (OA)
were randomly assigned to therapy with rofecoxib (25 or
50 mg/day), ibuprofen, or placebo. Patients were allowed to
take acetaminophen, non-NSAIDs, or an antacid during the
trial. Patients in the rofecoxib and placebo groups had lower
rates of endoscopic ulcers than did patients in the ibuprofen
group at 12 weeks; patients in both rofecoxib groups also had
lower rates of endoscopic ulcers at 24 weeks (P < 0.001 for
comparisons with ibuprofen). The rofecoxib and placebo
groups did not differ for any gastrointestinal outcome,
whereas efficacy or relief of arthritis related symptoms was
similar in the rofecoxib and ibuprofen groups.
The Vioxx Gastrointestinal Outcomes Research (VIGOR) trial
[7] was the first large-scale trial to provide evidence that
COX-2 inhibitors minimize the risk for upper gastrointestinal
adverse effects. The study enrolled 8076 patients with
rheumatoid arthritis (RA) aged 50 years or older (or at least
40 years of age and receiving glucocorticoid therapy) to
treatment with either rofecoxib 50 mg/day or naproxen
500 mg twice daily. Over 9 months of follow up the efficacy of
rofecoxib and naproxen were equivalent; however, the incidence
of confirmed upper gastrointestinal adverse events per 100
patient-years in the rofecoxib group was less than half that
observed in the naproxen group. In a post hoc analysis of the
trial, about 40% of the gastrointestinal bleeding events were in
the lower gastrointestinal tract; these were also reduced by
more than half in patients who received rofecoxib [8].
The Celecoxib Long-term Arthritis Safety Study (CLASS) [9]
provided additional evidence that COX-2 inhibitors minimize
risk for gastrointestinal events. In this study 8059 patients
with OA or RA aged 18 years or older were randomly
assigned to therapy with celecoxib 400 mg twice daily (two
times the maximum recommended dose for RA and four times
the maximum recommended dose for OA), ibuprofen 800 mg
three times daily, or diclofenac 75 mg twice daily. Patients
were permitted to receive aspirin if indicated for cardio-
vascular prophylaxis. During the 6-month treatment period,
among patients receiving celecoxib, the annualized incidence
of upper gastrointestinal complications alone and in
combination with symptomatic ulcers was half that observed
in patients who received the conventional NSAIDs.
Recently released data also suggest that, in addition to
minimizing ulcers and their complications, COX-2 inhibitors
improve the tolerability of anti-inflammatory therapy compared
with that achieved with conventional NSAIDs plus a PPI. A
multicenter, double blind, placebo controlled trial of healthy
adults that employed video capsule endoscopy [10] found an
average of only 0.32 (± 0.10) small bowel mucosal breaks
among patients receiving celecoxib 200 mg twice daily
compared with 2.99 (± 0.51) for those taking naproxen 500 mg
twice daily plus omeprazole 20 mg once daily (P< 0.001).
Similar reductions in gastrointestinal risk were observed with
the newer COX-2 inhibitors valdecoxib, etoricoxib, and
lumiracoxib [11-13].
It is important to note that in comparative trials, no differences
in efficacy were observed between the COX-2 selective
agents and the NSAID comparators. These data indicate that
COX-2 inhibitors should not be viewed as more efficacious
replacements for traditional NSAIDs; instead, following a
careful risk/benefit analysis they should be considered
appropriate in some patients at high risk for gastrointestinal
adverse effects or in patients who require anti-inflammatory
therapy for arthritis who do not tolerate the gastrointestinal
effects of nonselective NSAIDs.
Cardioprotective effects of aspirin
The benefits of aspirin in the secondary prevention of
cardiovascular events are well established; highly suggestive
data also support the use of aspirin for primary prevention.
Meta-analyses of randomized trials indicate that antiplatelet
therapy prevents serious cardiovascular events across aS16
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broad range of high risk patients [14]. The 1994 Antiplatelet
Trialists’ Collaboration [14] found that aspirin therapy
resulted in an approximately 25% reduction in the risk for
subsequent vascular events regardless of age, sex, blood
pressure, or diabetes. In absolute terms, this benefit
translated to avoidance of between 20 and 40 vascular
events per 1000 high risk patients treated for 1 year. A
second meta-analysis of 287 randomized studies, enrolling a
total of 212,000 patients, confirmed the same results [15].
Large-scale studies have also shown that aspirin confers a
substantially reduced risk for myocardial infarction (MI) in the
primary prevention of cardiovascular events [16]. These
studies have led to recommendations for aspirin therapy as a
primary prevention strategy for the majority of at-risk patients,
and as secondary prevention for nearly all patients with prior
evidence of cardiovascular disease [17]. Indeed, many
persons at low risk for cardiovascular events take low dose
aspirin in response to publicity surrounding the results of
these trials. However, recent data from the Women’s Health
Study [18] suggest that, although aspirin lowers the risk for
stroke in women, it does not significantly reduce the risk for
MI or death from cardiovascular causes.
Cardiovascular risk in patients receiving
NSAIDs and COX-2 inhibitors
Current data do not support extrapolation of the cardio-
protective effects of aspirin to other NSAIDs. Aspirin exerts
its antiplatelet effects by irreversibly acetylating a serine
residue in platelet COX-1, inhibiting the production of
thromboxane A2 for the lifetime of the platelet because the
platelet lacks the machinery to synthesize new COX [19,20].
In contrast, conventional NSAIDs bind reversibly at the active
site of the enzyme, depressing thromboxane A2 production
for only part of the dosing interval [21]. Case–control
analyses confirm that the incomplete and reversible inhibition
of COX by NSAIDs is unlikely to produce clinically detectable
cardiovascular protection comparable to that achieved by
low-dose aspirin [22-24].
Data from the VIGOR trial [7] were the first to suggest
unusual cardiovascular risk among patients receiving
rofecoxib. In this study, patients with RA received a mean of
9 months of rofecoxib 50 mg/day – a dose that is two to four
times higher than that usually recommended for long-term
treatment of arthritis. It should be noted that patients enrolled
in the VIGOR trial were not permitted to take aspirin and
other NSAIDs after randomization. Although the overall
mortality rate and rate of death from cardiovascular causes
were similar in the rofecoxib and naproxen arms, the rate of
nonfatal MI was significantly lower in the naproxen treated
group (0.1%) than in the rofecoxib group (0.4%). This
difference was largely due to a high rate of MI among patients
at high risk for coronary events. Among patients who did not
have an indication for secondary prophylaxis with aspirin, the
rates of MI were similar in the two treatment groups.
Some have attributed this difference in risk to a
cardioprotective effect associated with naproxen, but this
interpretation has been controversial [25,26]. In interpreting
results of VIGOR it is important to be aware that this
randomized controlled trial was designed to assess
gastrointestinal effects. Cardiovascular events were not
prespecified as outcomes and therefore were recorded only
from spontaneous reports of investigators, without any
standardized definitions and without prospective balancing of
treatment arms for cardiovascular risk. Hence, strictly
speaking, the data are hypothesis generating rather than
hypothesis testing with respect to cardiovascular risk.
However, a recent meta-analysis of 18 randomized controlled
trials and 11 observational studies of rofecoxib [27] support
the cardiovascular findings of VIGOR. Overall, patients who
received rofecoxib in these studies were at a 2.3-fold
increased risk for MI compared with those receiving placebo
or other NSAIDs. Importantly, the findings of the meta-
analysis were largely driven by the VIGOR data and, like
VIGOR, none of the other trials included in the meta-analysis
had prespecified documentation or definition of
cardiovascular events.
Nonetheless, the results of VIGOR gain credibility because
similar results were reported in the Adenomatous Polyp
Prevention on Vioxx (APPROVe) trial [28], a study of patients
with a history of colorectal adenomas in which cardiovascular
events were prospectively defined and collected. The 2586
study subjects were randomly assigned to therapy with
rofecoxib 25 mg/day or placebo. Among patients assigned to
rofecoxib, 46 patients had a confirmed cardiovascular event
(acute MI, stroke, or sudden death) during 3059 patient-years
of follow up, as compared with 26 patients in the placebo
group during 3327 patient-years of follow up, representing a
1.92-fold increase in risk for cardiovascular events associated
with rofecoxib. A divergence in risk for serious cardiovascular
events was observed after 18 months of therapy (Fig. 1),
primarily reflecting a greater number of MIs and strokes in the
rofecoxib group.
An increase in cardiovascular events has also been observed
in patients who received valdecoxib and its intravenous pro-
drug parecoxib as treatment for postoperative pain following
coronary artery bypass grafting [29]. After an initial, small
study (CABG-1) suggested increased cardiovascular risk
with sequential therapy consisting of intravenous parecoxib
followed by oral valdecoxib, a second study (CABG-2) was
undertaken in 1671 patients, who were randomly assigned to
one of the following groups: intravenous parecoxib for at least
3 days, followed by oral valdecoxib through to day 10;
intravenous placebo followed by oral valdecoxib; and placebo
alone for 10 days. Compared with the group receiving
placebo alone, a higher proportion of patients receiving
parecoxib and valdecoxib or placebo and valdecoxib suffered
at least one confirmed adverse event (4.0% in the placeboS17
group versus 7.4% in the parecoxib + valdecoxib and
valdecoxib alone groups). Cardiovascular adverse events
(e.g. MI, cardiac arrest, stroke, and pulmonary embolism)
were significantly more frequent in the group of patients who
received parecoxib plus valdecoxib than in those who
received placebo (2.0% versus 0.5%; P = 0.03). These data
indicate that even short-term COX-2 inhibition, with the drugs
and doses employed in this study, is associated with an
increase in cardiovascular events in some subsets of patients
with coronary artery disease.
In contrast to the results observed in the VIGOR and
APPROVe trials, no between group differences were
detected in the incidence of cardiovascular events among
patients enrolled in the CLASS trial [9], regardless of aspirin
use. Similarly, in a meta-analysis of multiple trials involving
more than 31,000 patients with arthritis [30] there was no
significant difference in MI frequency between patients taking
celecoxib and those receiving placebo, any nonselective
NSAID, or, specifically, naproxen, regardless of concomitant
aspirin use. Celecoxib use was associated with a tendency
toward a lower risk for MI in all patients (relative risk = 0.85,
95% confidence interval [CI] 0.23–3.15) and in those not
receiving aspirin (relative risk = 0.60, 95% CI 0.11–3.29)
compared with placebo (Fig. 2) [30]. However, like VIGOR
and the rofecoxib meta-analysis, CLASS and the celecoxib
studies included in the meta-analysis did not prospectively
define cardiovascular events or their documentation; more-
over, like the rofecoxib studies (other than VIGOR and, later,
APPROVe), the randomized controlled celecoxib studies
were of relatively short duration.
Based on experience with VIGOR and APPROVe, cardio-
vascular event documentation and adjudication were
prospectively mandated before trial completion in the several
randomized trials of celecoxib for prevention of colonic
adenomas and for retardation of progression of Alzheimer’s
disease. In one of these trials (Adenoma Prevention with
Celecoxib [APC]) [31], cardiovascular events segregated
significantly with celecoxib among 2035 patients with a
history of colorectal neoplasia. In this study patients were
randomly assigned to 200 mg or 400 mg celecoxib twice
daily or to placebo. During a follow-up period of
2.8–3.1 years, the composite end-point of death from
cardiovascular causes, myocardial infarction, stroke, or heart
failure was reached by 7 out of 679 patients in the placebo
group (1.0%), 16 out of 685 patients in the celecoxib 200 mg
twice daily group (2.3%, 95% CI 0.9% to 5.5%; P < 0.05),
and 23 out of 671 patients in the celecoxib 400 mg twice
daily group (3.4%, 95% CI 1.4% to 7.8%; P < 0.05).
Approximately half of the events in the celecoxib groups were
MI [31]. These findings led the trial’s data and safety
monitoring board to recommend study discontinuation before
its planned completion.
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Figure 1
Cumulative incidence of confirmed serious thrombotic events. Vertical
lines indicate 95% confidence intervals. Data are from the Adenomatous
Polyp Prevention on Vioxx (APPROVe) Trial [28]. Reproduced with
permission from [28]. Copyright © 2005 Massachusetts Medical
Society. All rights reserved.
Figure 2
Cardiovascular risk in patients with arthritis: celecoxib versus NSAIDs, naproxen, or placebo. Shown is a summary of the risk for death, myocardial
infarction, and stroke for celecoxib relative to nonsteroidal anti-inflammatory drugs (NSAIDs), naproxen, or placebo in patients with arthritis [30].
*P = nonsignificant. Reproduced with permission from Elsevier [30].S18
The results of the other randomized trials have not yet been
published, fully adjudicated, or presented in public in their
entirety, but a recent presentation to the US Food and Drug
Administration indicated that in one of them (Prevention of
Spontaneous Adenomatous Polyps [PreSAP] trial) no
difference was seen in the frequency of cardiovascular events
among patients receiving placebo and those receiving
celecoxib (total dose 400 mg/day). In the Alzheimer’s
Disease Anti-Inflammatory Prevention Trial (ADAPT), stopped
prematurely because of cessation of APC, there also was no
evidence that either naproxen 220 mg twice daily or
celecoxib 200 mg twice daily was associated with an
increased risk for cardiovascular events. The results of such
trials are difficult to interpret because of the small numbers of
events that occur in each; interpretation may be facilitated by
pooling the data from all the relevant trials when these are
fully adjudicated and are made publicly available.
An additional source of useful data on cardiovascular risk is
available from large epidemiologic studies that have been
facilitated in recent years by massive medical insurance
databases on drug prescriptions and discharge diagnoses
following hospitalizations. These epidemiologic studies suffer
from lack of randomization and the resulting potential for
unintentional channeling biases, from lack of rigorous
documentation of drug actually taken and of nonprescription
drugs administered concomitantly, and from dependence on
diagnoses defined to meet coding requirements for insurance
payments, without supporting documentation or detailed
event descriptions. However, they have an advantage over
randomized clinical trials in that, unlike randomized trials,
which typically exclude 90% of the population at risk so as to
avoid influences that might confound unambiguous data
interpretation, the large databases include a highly
representative proportion of the populations of interest. As a
result, estimates of absolute event risk drawn from these
database studies are likely to reflect more realistically the
expectations for the population at large than do event rates
drawn from randomized clinical trials.
Several recent epidemiologic studies indicate that the
cardiovascular risk associated with COX-2 inhibitors generally
is similar to that in patients receiving conventional nonselective
NSAIDs, although small but potentially important within-group
and between-group variability in cardiovascular risk may exist.
For example, among high risk patients receiving non-naproxen
NSAIDs, Shaya and colleagues [32] collected medical and
prescription claims data on 1005 patients using COX-2
inhibitors and 5245 patients using nonselective NSAIDs.
Overall, the odds of experiencing a cardiovascular event
among patients who were using COX-2 inhibitors was 1.09
compared with patients using nonnaproxen NSAIDs.
Another retrospective cohort study using a large state
Medicaid database [33] illustrates the differences in risk that
may be associated with usage of individual NSAIDs and
COX-2 inhibitors (Fig. 3). In this study the risk for acute MI
and fatal coronary heart disease was compared between
patients receiving rofecoxib, celecoxib, ibuprofen, and
naproxen. Patients aged between 50 and 84 years who did
not have life-threatening noncardiovascular illnesses were
eligible for inclusion in the analysis. Of the new drug users in
the study, patients who received more than 25 mg/day
rofecoxib exhibited a significantly higher incidence of serious
cardiovascular events than did those receiving other NSAID
treatments, including low-dose rofecoxib (≤25 mg/day;
P = 0.024). Compared with celecoxib, the high-dose
(>25 mg/day) rofecoxib group exhibited 2.2 times the rate of
serious coronary heart disease events (P = 0.014).
Among the largest epidemiologic studies was a nested
case–control analysis of information from the Kaiser-
Permanente database [34]. This study, involving data from
more than 1.3 million patients and 2.3 person-years of follow
up, found that rofecoxib at doses above 25 mg/day was
associated with a threefold higher incidence of MI and/or
cardiac deaths than were recorded among nonusers or
remote users of anti-inflammatory drugs. Rofecoxib at doses
of 25 mg/day or less was also associated with significantly
more events than among remote drug users, with an absolute
rate comparable to those of several conventional NSAIDs.
Interestingly, in this study celecoxib nominally was associated
with a lower event rate than that seen in remote drug users
(not a statistically significant finding, although the celecoxib
event rate was significantly lower than that associated with
naproxen, among other conventional NSAIDs).
Increased cardiovascular risk in patients receiving
NSAIDs and COX-2 inhibitors: some plausible
pathophysiologic bases
All NSAIDs, conventional and COX-2 selective, have the
capacity to increase sodium and water retention and thereby
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Figure 3
Deaths associated with NSAID induced gastrointestinal damage versus
other causes. Data from Ray and coworkers [33]. Numbers (n) are
person-years. *P = 0.024 versus reference; †P = 0.014 versus celecoxib
(2.20 [1.17–4.10]). CI, confidence interval; NSAID, nonsteroidal anti-
inflammatory drug. Reproduced with permission from Elsevier [33].S19
to increase blood pressure and cause or potentiate
congestive heart failure. Blood pressure has an important
influence on cardiovascular event rates; hypertension is a
primary risk factor for cardiovascular events. Epidemiologic
data indicate that an average blood pressure increase of even
2–3 mmHg, which is achievable with some NSAIDs and
COX-2 inhibitors, can have a measurable impact on cardio-
vascular risk. Admission rates for heart failure in elderly
patients are substantially higher among those who receive
rofecoxib or nonselective NSAIDs than among those not
receiving these drugs; however, celecoxib has not been
associated with an increase in risk of admission for heart
failure [35]. Heart failure risk also may be related to NSAID
associated increases in blood pressure. An early meta-analysis
[36] found that, when data from all nonselective NSAIDs
(including aspirin) were pooled, supine mean blood pressure
was increased by 5.0 mmHg compared with non-use.
The Celecoxib Rofecoxib Efficacy and Safety in
Comorbidities Evaluation Trial (CRESCENT) investigators
[37] reported that patients with hypertension, OA, and type 2
diabetes treated with rofecoxib 25 mg/day, but not those
treated with celecoxib 200 mg/day or naproxen 500 mg twice
daily, had a significant increase in 24 hour systolic blood
pressure (130.3 increasing to 134.5 mmHg; P < 0.001) after
6 weeks of therapy. This suggests that use of these agents
may result in different rates of cardiovascular adverse events.
A more recent meta-analysis of COX-2 inhibitors [38] found
that, overall, these agents were associated with a higher
relative risk for hypertension than placebo. In comparison with
celecoxib, rofecoxib was associated with a 50% greater risk
for developing clinically important systolic blood pressure
elevation. It appears that all NSAIDs – both conventional and
COX-2 selective – have the capacity to increase sodium and
water retention and to cause or potentiate hypertension and
heart failure, although celecoxib appears to have a lower
propensity to cause blood pressure elevations than does
rofecoxib. These data suggest that a plausible explanation for
the apparent association of NSAIDs and COX-2 inhibitors
with cardiovascular risk is the effect of these drugs on blood
pressure. Fortunately, this is a remediable problem because
the blood pressure effects of the drugs can usually be
reversed with appropriate therapy.
Another mechanistic hypothesis has been advanced for the
adverse cardiac effects of COX-2 inhibitors [39]. Data
indicate that COX-2 activity, rather than COX-1, is the
dominant source of prostaglandin I2 in the human epithelium.
Prostaglandin I2 is involved in inhibiting platelet aggregation,
in causing vasodilation, and in preventing the proliferation of
vascular smooth muscle cells. In contrast, thromboxane A2,
which is largely produced by the COX-1 enzyme, is involved
in platelet aggregation, vasoconstriction, and smooth muscle
proliferation. Although aspirin and traditional NSAIDs
suppress the activities of both COX-1 and COX-2, and
therefore reduce both thromboxane A2 and prostaglandin I2,
COX-2 inhibitors selectively suppress the production of
prostaglandin I2 without affecting thromboxane A2 synthesis.
As a result, patients in whom COX-2 is selectively suppressed
might be expected to have elevated blood pressure,
accelerated atherogenesis, and an exaggerated thrombotic
response to plaque rupture. This attractive hypothesis does
not easily account for the observation from clinical trials,
discussed above, that aspirin use does not appear to have
influenced the relation of cardiovascular event rates observed
between COX-2 inhibitors and comparators among patients
in randomized trials. In addition, pharmacoepidemiologic
studies show approximately similar event rates with the
nonselective NSAIDs and with at least some doses of certain
COX-2 selective inhibitors. Thus, any relation between
COX-2 inhibition and cardiovascular events is likely to be
more complex than can be explained solely by an imbalance
between COX-1 and COX-2 inhibition.
An additional hypothesis suggests that at least some anti-
inflammatory drugs may prevent cardiovascular events at
some doses because of salutary effects on vascular
endothelium or on the inflammatory components of athero-
sclerosis. One study, conducted by Chenevard and colleagues
[40], found that COX-2 inhibition improved endothelium
dependent vasodilation and reduced low-grade chronic
inflammation and oxidative stress in patients with severe
coronary artery disease. Indeed, this may be particularly
important in systemic inflammatory conditions, such as adult
RA, that appear to enhance the risk for cardiovascular events,
presumably by potentiating vascular inflammation.
‘Class’ effects of NSAIDs and COX-2 inhibitors
Taken together, data from clinical trials and epidemiologic
studies suggest that NSAIDs as a group may potentiate
cardiovascular risk at some doses, whether they are selective
for COX-2 or not. The data also suggest some interdrug
variability in these effects, and a potentially important relation
of cardiovascular effects and dose with at least some of
these drugs. The problem seems most apparent when
rofecoxib is employed at doses above 25 mg/day, but
conventional NSAIDs at some commonly used doses may be
associated with similar problems. Among the COX-2 agents
tested thus far at their labeled doses, cardiovascular and
gastrointestinal safety profiles generally have been similar,
although studies suggest that celecoxib may have a slightly
better safety profile than other COX-2 inhibitors or NSAIDs. A
possible basis for this is suggested by the study conducted
by Whelton and colleagues [41], in which 810 elderly
patients with OA and hypertension were randomly assigned
to therapy with once daily celecoxib 200 mg or rofecoxib
25 mg. Nearly twice as many patients who received rofecoxib
experienced edema compared with those who received
celecoxib. Moreover, systolic blood pressure increased
significantly in 17% of patients who received rofecoxib,
compared with 11% of patients who received celecoxib.
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Mean blood pressure after 6 weeks of therapy was increased
by 2.6 mmHg in patients who received rofecoxib; in contrast,
blood pressure was reduced by 0.5 mmHg in the celecoxib
group.
Consequences of co-therapy with aspirin
Among patients at high risk for cardiovascular events, 46% of
women and 59% of men take aspirin; even among low-risk
patients, more than 20% may be taking aspirin [42]. The
ready availability of over-the-counter NSAIDs and aspirin
inevitably means that many patients take aspirin, conventional
NSAIDs, and/or COX-2 selective agents concomitantly. A
telephone survey [43], conducted in patients enrolled in
CLASS, indicated that the majority of patients, regardless of
age, were taking aspirin, acetaminophen, and/or conventional
NSAIDs during the study (Table 1).
Gastrointestinal risk
The gastroprotective benefit of COX-2 inhibitors is partially
or, in some patients, totally ameliorated if aspirin is used for
cardiovascular prophylaxis. In a study conducted by Schnitzer
and colleagues [44] 18,325 patients aged 50 years or older
were randomly assigned to lumiracoxib 400 mg once daily,
naproxen 500 mg twice daily, or ibuprofen 800 mg three
times daily for 1 year. Patients were stratified by low dose
aspirin use and age. Consistent with the results of previous
studies of COX-2 inhibitors, the cumulative incidence of ulcer
complications was reduced by 79% among patients who
received lumiracoxib (P < 0.0001), but the reduction was
smaller and did not reach statistical significance among
patients who received concomitant aspirin. More than 20% of
patients enrolled in the CLASS study [9] were receiving
concomitant low dose aspirin.
Recent evidence suggests that gastrointestinal benefits may
also be lost in patients who receive warfarin together with
anti-inflammatory drugs. In a nested case–control analysis,
Battistella and colleagues [45] quantified the gastrointestinal
risk in warfarin users treated with nonselective NSAIDs or
COX-2 inhibitors. During the study period, 361 (0.3%) out of
98,821 elderly patients who had received warfarin were
admitted with gastrointestinal hemorrhage. These patients
were 1.9-fold more likely to be receiving NSAIDs, 1.7-fold
more likely to be receiving celecoxib, and 2.4-fold more likely
to be taking rofecoxib than to be taking no anti-inflammatory
drugs before hospitalization.
Paradoxically, the introduction of COX-2 inhibitors has been
associated with an increase in hospitalization rates for upper
gastrointestinal hemorrhage. In an epidemiologic study
conducted by Mamdani and colleagues [46], billing records
for more than 1.3 million patients were assessed for the
interval between late 1994 and early 2002. During this time,
there was a 41% rise in NSAID use, which was entirely
attributable to increased use of COX-2 inhibitors. This
increase in NSAID use was accompanied by a 10% increase
in hospitalization rates for upper gastrointestinal hemorrhage
(Fig. 4). However, the increase in hospitalization rate was less
than one-quarter the increase in NSAID use. Moreover, it
cannot be inferred that hospitalization rates directly reflect the
impact of COX-2 inhibitor introduction; increased NSAID use
and increasing use of aspirin for cardiovascular prophylaxis
occurred during the same interval and might have importantly
influenced the hospitalization data.
Cardiovascular risk
Ibuprofen prevents the irreversible platelet inhibition induced
by aspirin [47]. This effect may be responsible for a
statistically and clinically significant increase in risk for
mortality in users of aspirin plus ibuprofen compared with
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Table 1
Aspirin use
%
Nonaspirin 
Age (years) Aspirin Acetaminophen NSAIDsa
37–55 (n = 20) 25 35 20
56–65 (n = 58) 50 45 10
66–75 (n = 127) 51 40 10
≥76 (n = 119) 48 45 8
Total (n = 324) 48 43 10
Shown are the percentages of long-term cyclo-oxygenase (COX)-2
inhibitor users taking aspirin, acetaminophen, or nonsteroidal anti-
inflammatory drugs (NSAIDs) by age group [43]. aNaproxen, sodium,
or ibuprofen. Reproduced with permission from [43].
Figure 4
Prevalence of NSAID use and rate of hospitalization for upper
gastrointestinal hemorrhage. Data from Mamdani and coworkers [46].
NSAID, nonsteroidal anti-inflammatory drug. Reproduced with
permission from [46].S21
users of ibuprofen alone [48]. In contrast, sustained exposure
to diclofenac, rofecoxib, or acetaminophen did not influence
the effects of aspirin on platelet function.
Conclusion
The data summarized here suggest that the risks and benefits
of conventional NSAIDs and COX-2 inhibitors must be
carefully weighed before making therapeutic decisions. In
clinical practice, the majority of patients with moderate to
severe arthritis who might benefit from NSAID or COX-2
inhibitor therapy are likely to be elderly, and therefore at
relatively higher risk for gastrointestinal and cardiovascular
adverse events than would younger individuals. These
patients are also more likely to be taking low-dose aspirin and
using over-the-counter NSAIDs for pain relief.
Selecting a combination of therapies that provides relief from
arthritis related symptoms, minimizes cardiovascular risk, and
preserves the gastrointestinal mucosa is a complex
challenge. Factors to consider include the interference of
certain NSAIDs, such as ibuprofen, with the antiplatelet
effects of aspirin; direct effects of nonselective NSAIDS and
of COX-2 inhibitors on fluid retention and blood pressure;
emerging data about cardiovascular risks associated with
these drugs; differences in the adverse gastrointestinal event
rates among NSAIDs and COX-2 inhibitors; and the
feasibility of co-therapy with gastroprotective agents.
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